Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Love Hemp: A Global CBD Heavyweight In The Making

Published 20/10/2021, 12:28
Updated 17/08/2023, 13:25

Love Hemp (AQUIS:LIFE) has established a leading presence in the UK CBD market and is looking to replicate this achievement globally. Key to its success will be product development, the introduction of new sales channels, both online and offline, and securing global distribution agreements. The company will continue brand development via large-scale marketing campaigns and leveraging agreements with the Ultimate Fighting Championship (UFC) and high-profile ambassadors such as British boxer Anthony Joshua.

Share price graph

Share price graph

Global expansion plans

While continuing to enhance its leading UK presence, Love Hemp is focused on the global CBD market, which Grand View Research values at US$2.8bn in 2020 and forecasts a CAGR of 21.1% in 2021–28e. Its partnership with UFC provides an ideal platform to penetrate the US market, given the 55 million UFC fans in the US alone (625 million worldwide), with a licensed range of UFC products in the pipeline. The distribution deal with eCargo Holdings announced in September 2021 is a first step into Asia in anticipation of easing regulations. High-profile brand ambassadors such as Anthony Joshua continue to raise awareness of Love Hemp as a wellness product.

An Amazon (NASDAQ:AMZN) vendor

Amazon UK invited Love Hemp to join its vendor platform and the company received initial orders in September 2021. Love Hemp expects the product range on the platform to grow as the authorisation process with Amazon continues and a dedicated virtual store is planned.

Strong FY21 growth despite lockdown

In the July 2021 trading update, Love Hemp reported a 60% increase in revenue to £4.3m for FY21, with the number of consumer accounts more than doubling to almost 37,000 and a 244% jump in units sold to 188,865. Online sales accounted for approximately 60% of revenues in FY21, with the remainder via major UK retailers such as Holland & Barrett, Boots and Alliance Healthcare. The balance sheet has been strengthened via a c £5m reduction in debt, including the conversion of convertible debt to equity.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Milestones

Love Hemp raised over £10m in equity financing in FY21, including initial investment from institutional investors. Use of funds include the establishment of new production facilities (complete) and fulfilling the international growth strategy. Given the size of the international opportunity, Love Hemp expects revenues to at least double in FY22 from £4.3m in FY21. It is on track to list on the London Stock Exchange in the coming months, a move that can be expected to widen the pool of potential investors and enhance liquidity.

Historical financials

Historical financials

For more, read the PDF below:

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.